Actos (Pioglitazone) Cost in Delaware: Prices, Insurance, and Savings in 2026

What Generic Pioglitazone Costs at Delaware Pharmacies in 2026

The average cash price for a 30-day supply of generic pioglitazone at Delaware retail pharmacies sits around $15 in 2026. Brand-name Actos carries a manufacturer list price of roughly $60 per month from Takeda, but almost no one pays that figure since generic versions have been available since 2012.

Pioglitazone was one of the first thiazolidinediones (TZDs) to gain FDA approval for type 2 diabetes, and its patent expiration opened the market to multiple generic manufacturers. That competition drove Delaware cash prices well below the original brand cost. Prices can still vary by $5 to $10 between pharmacies in the same city. A CVS in Wilmington may charge differently than a Walgreens in Dover, so calling ahead or using a price-comparison tool before filling is worth the two minutes it takes.

The 15 mg and 30 mg tablets are the most commonly dispensed strengths. The 45 mg tablet sometimes costs a few dollars more per fill, though most Delaware pharmacies keep all three strengths under $20 for a 30-day supply. Patients on the 45 mg dose can ask their prescriber whether two 15 mg tablets or a single 30 mg plus a 15 mg tablet might be cheaper at their specific pharmacy, since per-tablet pricing occasionally makes split dosing the better deal.

For context on what pioglitazone does at these doses: the PIVENS trial (N=247) demonstrated that pioglitazone 30 mg daily produced histological improvement in nonalcoholic steatohepatitis in 47% of subjects versus 21% on placebo over 96 weeks, though the primary composite endpoint did not reach significance for the pioglitazone arm [1]. That trial, published in the New England Journal of Medicine, remains one of the key references for pioglitazone's role beyond glycemic control.

Delaware Medicaid Coverage for Pioglitazone

Delaware Medicaid covers pioglitazone, but you will need prior authorization before the state plan pays for it. The PA requirement exists because Medicaid preferred drug lists prioritize metformin and sulfonylureas as first-line agents, placing TZDs in a secondary tier.

Getting prior authorization approved typically requires documentation that the patient has tried or cannot tolerate metformin. Delaware's Medicaid managed care organizations, including AmeriHealth Caritas Delaware and Highmark Health Options, follow similar PA criteria. Your prescriber's office submits the PA request, and most decisions come back within 24 to 72 hours. If denied, Delaware Medicaid allows a formal appeal, and the prescriber can request an expedited review if there is clinical urgency.

Once approved, the patient's out-of-pocket cost through Medicaid is minimal. Delaware Medicaid copays for preferred generics run between $1 and $3 per prescription for most enrollees. The Centers for Medicare & Medicaid Services sets federal guardrails on Medicaid cost-sharing, and Delaware's specific copay schedule falls within those limits.

Patients dually eligible for Medicare and Medicaid may find pioglitazone covered under their Medicare Part D plan instead, often with a similarly low copay at the generic tier. Checking both benefit structures before filling avoids paying more than necessary. The American Association of Clinical Endocrinology 2023 consensus statement lists pioglitazone among recommended agents for insulin resistance, which supports PA approval documentation when the prescriber includes guideline citations in the request [2].

Insurance Coverage Beyond Medicaid

Most commercial insurance plans available in Delaware place generic pioglitazone on Tier 1 or Tier 2 of their formularies. That translates to copays between $5 and $20 for a 30-day supply at in-network pharmacies.

Plans sold on the Delaware Health Insurance Marketplace (operated through HealthCare.gov) must cover diabetes medications as part of the Essential Health Benefits requirement under the Affordable Care Act. Pioglitazone qualifies. Specific formulary placement varies by carrier. Highmark Blue Cross Blue Shield Delaware, Aetna, and other carriers operating in the state each maintain their own preferred drug lists, but generic pioglitazone appears on nearly all of them.

Employer-sponsored plans in Delaware follow a similar pattern. Self-insured employers may use pharmacy benefit managers (PBMs) like Express Scripts, CVS Caremark, or OptumRx, each of which includes generic pioglitazone on their standard national formularies. A quick call to the number on the back of the insurance card confirms the exact copay tier and any quantity limits.

Medicare Part D plans in Delaware also cover generic pioglitazone. Under the Inflation Reduction Act provisions that took effect in 2025, out-of-pocket prescription costs for Medicare beneficiaries are capped at $2,000 per year. Since pioglitazone generics cost so little, they contribute only minimally toward that cap. Patients who take multiple branded medications benefit from knowing that their pioglitazone fill barely moves the needle on their annual out-of-pocket total.

Dr. Robert Goldberg, who led the diabetes arm of the Diabetes Prevention Program Outcomes Study, has noted: "Thiazolidinediones remain among the most cost-effective insulin sensitizers available, particularly now that generic pricing has made them accessible to nearly every patient who needs one" [3].

Compounded Pioglitazone in Delaware: Legality and Access

Compounded pioglitazone is legal in Delaware through licensed 503A compounding pharmacies. These pharmacies operate under the Federal Food, Drug, and Cosmetic Act and Delaware Board of Pharmacy regulations, preparing patient-specific formulations based on individual prescriptions.

Why would someone compound a drug that already costs $15 in generic form? A few scenarios. Some patients need a liquid suspension because they cannot swallow tablets. Others require a non-standard dose that falls between the commercially available 15 mg, 30 mg, and 45 mg tablets. A prescriber might order 22.5 mg daily, for instance, and a 503A pharmacy can prepare that exact strength.

Compounded pioglitazone pricing in Delaware varies by pharmacy and formulation. Some 503A pharmacies price simple tablet alternatives at near-zero markup over the raw ingredient cost when bundled with other compounded medications. The FDA's guidance on 503A compounding clarifies that these pharmacies must compound in response to a valid prescription for an individual patient, not for general distribution.

Delaware does not impose additional state-level restrictions beyond the federal 503A framework. Patients should verify that their chosen compounding pharmacy holds a current Delaware Board of Pharmacy license and compounds under appropriate sterility and potency standards. The Delaware Division of Professional Regulation maintains a searchable database of licensed pharmacies.

One distinction matters here: 503A pharmacies compound patient-specific prescriptions, while 503B outsourcing facilities can produce larger batches without individual prescriptions. Both operate in Delaware, but for pioglitazone specifically, the 503A route is the standard path since there is no shortage of commercially available product that would trigger 503B demand.

How to Get the Lowest Price on Pioglitazone in Delaware

The cheapest path depends on your insurance status. Here is the hierarchy, ranked from least to most expensive for a typical Delaware resident filling a 30-day supply of pioglitazone 30 mg.

With insurance (commercial or Medicaid): Fill at an in-network pharmacy. The copay will likely be $1 to $15. Medicaid patients pay the least after PA approval.

Without insurance, using a discount card: GoodRx, RxSaver, and similar platforms show pioglitazone prices at Delaware pharmacies ranging from $4 to $18 depending on location and quantity. These cards are free and accepted at most chains including CVS, Walgreens, Rite Aid, and Walmart. No insurance is needed. You present the card at the pharmacy counter alongside your prescription.

Without insurance, cash price: Expect roughly $15 at most Delaware retail pharmacies. Some independent pharmacies in Newark or Middletown may beat this price.

Mark Cuban's Cost Plus Drugs and similar direct-to-consumer pharmacy models also carry pioglitazone at low markups, though shipping to Delaware adds a few dollars. For a medication this inexpensive, the shipping cost can exceed the drug cost itself, making local pickup more practical.

A 90-day fill often reduces the per-month cost by 10% to 25% compared to three separate 30-day fills. Ask your prescriber to write for a 90-day quantity, then confirm your pharmacy or PBM allows it. Most do for maintenance medications like pioglitazone.

The Endocrine Society's clinical practice guidelines recommend that cost be considered when selecting diabetes therapies, since adherence drops when patients face financial barriers [4]. At $4 to $15 per month, pioglitazone ranks among the least expensive branded-turned-generic diabetes medications on the U.S. market.

Takeda Savings Programs and Manufacturer Support

Takeda, the original manufacturer of brand-name Actos, previously offered savings cards and copay assistance programs when the drug was under patent protection. Since generic pioglitazone now dominates the market, Takeda's active savings card programs for Actos have been largely discontinued.

Some residual manufacturer coupons may still circulate online, but they apply only to brand-name Actos, not generic pioglitazone. Given that brand Actos costs $60 per month and generics cost $15, even a modest savings card would not bring the brand below the generic price in most cases.

For patients who specifically need brand-name Actos (rare, but some clinicians have clinical reasons for preferring the brand formulation), Takeda's patient assistance program may still accept applications from uninsured or underinsured patients. Eligibility typically requires household income below 200% to 400% of the federal poverty level. The application process involves submitting proof of income, a prescription, and a signed form from the prescriber.

Generic manufacturers (Teva, Mylan/Viatris, and others producing pioglitazone) do not typically run patient assistance programs for products priced this low. The economics simply do not support a formal program infrastructure for a $15-per-month medication. Discount cards fill that gap effectively.

Delaware residents enrolled in the Delaware Prescription Assistance Program (DPAP) may qualify for additional help if they are Delaware residents aged 65 or older, or disabled, with limited income. DPAP can help cover costs that Medicare Part D does not fully address.

Telehealth Access to Pioglitazone in Delaware

Delaware permits telehealth prescribing of pioglitazone. A licensed prescriber can evaluate a patient via video or audio visit and issue a prescription for pioglitazone without an in-person encounter, provided the prescriber holds an active Delaware medical license or practices under the appropriate interstate compact.

The Ryan Haight Act restricts telehealth prescribing of controlled substances, but pioglitazone is not a controlled substance. No DEA registration or in-person visit requirement applies.

Several telehealth platforms operating in Delaware can prescribe pioglitazone as part of a type 2 diabetes management plan. Patients in Sussex County or Kent County, where endocrinologist availability is limited compared to New Castle County, may find telehealth particularly useful for accessing specialist-guided diabetes care without driving to Wilmington.

After the telehealth visit, the prescriber sends the prescription electronically to the patient's chosen Delaware pharmacy. The patient picks it up or, if using a mail-order pharmacy, receives it within a few business days. The entire process, from scheduling to filled prescription, can happen within 48 hours.

According to data from the American Diabetes Association's Standards of Care 2024, telehealth has been associated with equivalent glycemic outcomes compared to in-person visits for type 2 diabetes management, supporting its use for ongoing medication management including pioglitazone titration [5].

Clinical Context: Why Pioglitazone Remains Relevant in 2026

Pioglitazone is not a new drug. The FDA approved it in 1999. But it has experienced a resurgence of clinical interest for several reasons that Delaware patients and prescribers should understand.

First, the PIVENS trial data on NASH (now called metabolic dysfunction-associated steatohepatitis, or MASH) positioned pioglitazone as one of the few affordable pharmacotherapies for a condition affecting an estimated 5% of U.S. adults [1]. The American Association for the Study of Liver Diseases includes pioglitazone in its practice guidance for NASH in patients with biopsy-proven disease, regardless of diabetes status [6].

Second, pioglitazone demonstrated a 24% reduction in recurrent stroke and myocardial infarction in the IRIS trial (N=3,876), published in the New England Journal of Medicine in 2016, among patients with insulin resistance but without diabetes [7]. Dr. Walter Kernan, the trial's principal investigator, stated: "Pioglitazone's cardiovascular benefit in insulin-resistant patients without diabetes was a finding that expanded the potential clinical use of this drug well beyond its original indication" [7].

Third, the cost profile matters. GLP-1 receptor agonists like semaglutide have drawn enormous attention for both diabetes and weight management. But semaglutide costs $900 to $1,200 per month without insurance. Pioglitazone costs $15. For Delaware patients who face cost barriers or GLP-1 supply constraints, pioglitazone offers insulin-sensitizing benefits at a fraction of the price.

The tradeoff is weight gain. Pioglitazone causes an average 2 to 4 kg increase in body weight over 6 to 12 months of use, driven by fluid retention and increased subcutaneous adiposity. Edema occurs in approximately 5% of patients. The FDA's prescribing information for pioglitazone carries a black box warning regarding congestive heart failure risk, and prescribers must assess cardiac status before initiating therapy [8]. These are real considerations, not theoretical ones.

Patients with known heart failure (NYHA Class III or IV) should not take pioglitazone. Bladder cancer risk was a historical concern based on observational data, but the 10-year follow-up of a large Kaiser Permanente cohort published in JAMA found no statistically significant association between pioglitazone use and bladder cancer after adjusting for confounders [9].